Clinical utility of target-based next-generation sequencing for drug-resistant TB
In high TB burden countries, access to drug susceptibility testing is a major bottleneck. Targeted next-generation sequencing (tNGS) is a promising technology for rapid resistance detection. This study assessed the role of tNGS for the diagnosis of drug-resistant TB (DR-TB). A total of 161 samples f...
Saved in:
| Published in: | The international journal of tuberculosis and lung disease Vol. 27; no. 1; p. 41 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
France
01.01.2023
|
| Subjects: | |
| ISSN: | 1815-7920, 1815-7920 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | In high TB burden countries, access to drug susceptibility testing is a major bottleneck. Targeted next-generation sequencing (tNGS) is a promising technology for rapid resistance detection. This study assessed the role of tNGS for the diagnosis of drug-resistant TB (DR-TB).
A total of 161 samples from bacteriologically confirmed TB cases were subjected to tNGS using the Deeplex
Myc-TB kit and sequenced using the MiSeq platform. These samples were also processed for conventional phenotypic DST (pDST) using 13 drugs on Mycobacteria Growth Indicator Tube and line-probe assays (MTBDR
and MTBDR
).
There were 146 DR-TB and 15 drug-susceptible TB (DS-TB) samples. About 70% of patients with DR-TB had no previous TB treatment history. Overall, 88.2% had rifampicin-resistant/multidrug-resistant TB (RR/MDR-TB), 58.5% pre-extensively drug-resistant TB (pre-XDR-TB) and 9.2% had XDR-TB as defined by the WHO (2020). Around 8% (
= 13) of samples were non-culturable; however, identified 8 were resistant to first and second-line drugs using tNGS. Resistance frequency was similar across methods, with discordance in drugs less reliable using pDST or with limited mutational representation within databases. Sensitivities were aligned with literature reports for most drugs. We observed 10% heteroresistance, while 75% of strains were of Lineages 2 and 3.
Programme data supported tNGS in the diagnosis of DR-TB for early treatment using individualised regimens. |
|---|---|
| AbstractList | In high TB burden countries, access to drug susceptibility testing is a major bottleneck. Targeted next-generation sequencing (tNGS) is a promising technology for rapid resistance detection. This study assessed the role of tNGS for the diagnosis of drug-resistant TB (DR-TB).
A total of 161 samples from bacteriologically confirmed TB cases were subjected to tNGS using the Deeplex
Myc-TB kit and sequenced using the MiSeq platform. These samples were also processed for conventional phenotypic DST (pDST) using 13 drugs on Mycobacteria Growth Indicator Tube and line-probe assays (MTBDR
and MTBDR
).
There were 146 DR-TB and 15 drug-susceptible TB (DS-TB) samples. About 70% of patients with DR-TB had no previous TB treatment history. Overall, 88.2% had rifampicin-resistant/multidrug-resistant TB (RR/MDR-TB), 58.5% pre-extensively drug-resistant TB (pre-XDR-TB) and 9.2% had XDR-TB as defined by the WHO (2020). Around 8% (
= 13) of samples were non-culturable; however, identified 8 were resistant to first and second-line drugs using tNGS. Resistance frequency was similar across methods, with discordance in drugs less reliable using pDST or with limited mutational representation within databases. Sensitivities were aligned with literature reports for most drugs. We observed 10% heteroresistance, while 75% of strains were of Lineages 2 and 3.
Programme data supported tNGS in the diagnosis of DR-TB for early treatment using individualised regimens. BACKGROUND: In high TB burden countries, access to drug susceptibility testing is a major bottleneck. Targeted next-generation sequencing (tNGS) is a promising technology for rapid resistance detection. This study assessed the role of tNGS for the diagnosis of drug-resistant TB (DR-TB).METHODS: A total of 161 samples from bacteriologically confirmed TB cases were subjected to tNGS using the Deeplex® Myc-TB kit and sequenced using the MiSeq platform. These samples were also processed for conventional phenotypic DST (pDST) using 13 drugs on Mycobacteria Growth Indicator Tube and line-probe assays (MTBDRplus and MTBDRsl).RESULTS: There were 146 DR-TB and 15 drug-susceptible TB (DS-TB) samples. About 70% of patients with DR-TB had no previous TB treatment history. Overall, 88.2% had rifampicin-resistant/multidrug-resistant TB (RR/MDR-TB), 58.5% pre-extensively drug-resistant TB (pre-XDR-TB) and 9.2% had XDR-TB as defined by the WHO (2020). Around 8% (n = 13) of samples were non-culturable; however, identified 8 were resistant to first and second-line drugs using tNGS. Resistance frequency was similar across methods, with discordance in drugs less reliable using pDST or with limited mutational representation within databases. Sensitivities were aligned with literature reports for most drugs. We observed 10% heteroresistance, while 75% of strains were of Lineages 2 and 3.CONCLUSIONS: Programme data supported tNGS in the diagnosis of DR-TB for early treatment using individualised regimens.BACKGROUND: In high TB burden countries, access to drug susceptibility testing is a major bottleneck. Targeted next-generation sequencing (tNGS) is a promising technology for rapid resistance detection. This study assessed the role of tNGS for the diagnosis of drug-resistant TB (DR-TB).METHODS: A total of 161 samples from bacteriologically confirmed TB cases were subjected to tNGS using the Deeplex® Myc-TB kit and sequenced using the MiSeq platform. These samples were also processed for conventional phenotypic DST (pDST) using 13 drugs on Mycobacteria Growth Indicator Tube and line-probe assays (MTBDRplus and MTBDRsl).RESULTS: There were 146 DR-TB and 15 drug-susceptible TB (DS-TB) samples. About 70% of patients with DR-TB had no previous TB treatment history. Overall, 88.2% had rifampicin-resistant/multidrug-resistant TB (RR/MDR-TB), 58.5% pre-extensively drug-resistant TB (pre-XDR-TB) and 9.2% had XDR-TB as defined by the WHO (2020). Around 8% (n = 13) of samples were non-culturable; however, identified 8 were resistant to first and second-line drugs using tNGS. Resistance frequency was similar across methods, with discordance in drugs less reliable using pDST or with limited mutational representation within databases. Sensitivities were aligned with literature reports for most drugs. We observed 10% heteroresistance, while 75% of strains were of Lineages 2 and 3.CONCLUSIONS: Programme data supported tNGS in the diagnosis of DR-TB for early treatment using individualised regimens. |
| Author | Ndlovu, Z England, K Morales, M Isaakidis, P Oswal, V Sharma, J Hirani, N Joshi, A Iyer, A Mansoor, H Das, M Bharati, M Ferlazzo, G Chavan, V |
| Author_xml | – sequence: 1 givenname: H surname: Mansoor fullname: Mansoor, H organization: Médecins Sans Frontières, Mumbai, India – sequence: 2 givenname: N surname: Hirani fullname: Hirani, N organization: Grant Medical College, Sir Jamshedjee Jeejebhoy Group of Hospitals, Mumbai, India – sequence: 3 givenname: V surname: Chavan fullname: Chavan, V organization: Médecins Sans Frontières, Mumbai, India – sequence: 4 givenname: M surname: Das fullname: Das, M organization: Médecins Sans Frontières, Mumbai, India – sequence: 5 givenname: J surname: Sharma fullname: Sharma, J organization: Médecins Sans Frontières, Mumbai, India – sequence: 6 givenname: M surname: Bharati fullname: Bharati, M organization: Médecins Sans Frontières, Mumbai, India – sequence: 7 givenname: V surname: Oswal fullname: Oswal, V organization: National TB Elimination Programme, Mumbai, India – sequence: 8 givenname: A surname: Iyer fullname: Iyer, A organization: Médecins Sans Frontières, Mumbai, India – sequence: 9 givenname: M surname: Morales fullname: Morales, M organization: Médecins Sans Frontières, Mumbai, India – sequence: 10 givenname: A surname: Joshi fullname: Joshi, A organization: Grant Medical College, Sir Jamshedjee Jeejebhoy Group of Hospitals, Mumbai, India – sequence: 11 givenname: G surname: Ferlazzo fullname: Ferlazzo, G organization: Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa – sequence: 12 givenname: P surname: Isaakidis fullname: Isaakidis, P organization: Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa, Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece – sequence: 13 givenname: Z surname: Ndlovu fullname: Ndlovu, Z organization: Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa – sequence: 14 givenname: K surname: England fullname: England, K organization: Independent Consultant, Infectious Disease Microbiologist, Honolulu, Hawaii, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36853141$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtLAzEYRYNUrK0u3UqWblLzmEzSpRZfUBChrock82VImWZqkgH77y1YwdW9i8PhcmdoEocICN0wupBS6_uwLX274HxBmdBn6JJpJolacjr516dolvOWUs4YUxdoKmotBavYJfpY9SEGZ3o8ltCHcsCDx8WkDgqxJkOLI3wX0kGEZEoYIs7wNUJ0IXbYDwm3aexIghxyMbHgzeMVOvemz3B9yjn6fH7arF7J-v3lbfWwJq5SdSEeltZTqwSnSi1NJVvrla2tE9wyRaUQ3mnmmbbOAXCQrRDgOXdeGVXTls_R3a93n4bjolyaXcgO-t5EGMbccKWpqisp6BG9PaGj3UHb7FPYmXRo_m7gP7wJYlA |
| CitedBy_id | crossref_primary_10_1038_s41598_024_77947_w crossref_primary_10_1016_j_ebiom_2025_105875 crossref_primary_10_1371_journal_pgph_0004465 crossref_primary_10_1371_journal_pgph_0004718 crossref_primary_10_3892_mmr_2024_13277 crossref_primary_10_1080_22221751_2024_2392656 crossref_primary_10_3389_fcimb_2025_1497198 crossref_primary_10_1186_s12879_025_11227_4 crossref_primary_10_1016_S1473_3099_24_00263_9 crossref_primary_10_1128_jcm_01390_24 crossref_primary_10_1186_s13054_024_05009_8 crossref_primary_10_1093_ofid_ofad548 crossref_primary_10_1016_j_ijmmb_2024_100665 crossref_primary_10_3389_fmicb_2025_1615965 crossref_primary_10_1128_spectrum_04098_23 crossref_primary_10_1093_jambio_lxaf100 crossref_primary_10_3389_fmicb_2024_1403619 crossref_primary_10_56083_RCV5N4_096 crossref_primary_10_1128_spectrum_03127_24 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.5588/ijtld.22.0138 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1815-7920 |
| ExternalDocumentID | 36853141 |
| Genre | Journal Article |
| GroupedDBID | --- ..I 29J 2WC 5GY 5RE ACGFO ACPRK ADBBV AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL CGR CUY CVF DIK DU5 EBS ECM EIF EJD F5P H13 IPNFZ NPM OK1 P2P PQQKQ RIG TR2 7X8 |
| ID | FETCH-LOGICAL-c476t-fe9bf0b7320779a45dbf7b6bc32b170533fc81f18bccee2e5d33ef22cf7a760d2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 24 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000992517700009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1815-7920 |
| IngestDate | Fri Jul 11 10:39:23 EDT 2025 Mon Jul 21 05:42:54 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c476t-fe9bf0b7320779a45dbf7b6bc32b170533fc81f18bccee2e5d33ef22cf7a760d2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9879084 |
| PMID | 36853141 |
| PQID | 2780764530 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2780764530 pubmed_primary_36853141 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-01-01 20230101 |
| PublicationDateYYYYMMDD | 2023-01-01 |
| PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | France |
| PublicationPlace_xml | – name: France |
| PublicationTitle | The international journal of tuberculosis and lung disease |
| PublicationTitleAlternate | Int J Tuberc Lung Dis |
| PublicationYear | 2023 |
| SSID | ssj0021117 |
| Score | 2.4980056 |
| Snippet | In high TB burden countries, access to drug susceptibility testing is a major bottleneck. Targeted next-generation sequencing (tNGS) is a promising technology... BACKGROUND: In high TB burden countries, access to drug susceptibility testing is a major bottleneck. Targeted next-generation sequencing (tNGS) is a promising... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 41 |
| SubjectTerms | Databases, Factual Extensively Drug-Resistant Tuberculosis - diagnosis Extensively Drug-Resistant Tuberculosis - drug therapy High-Throughput Nucleotide Sequencing Humans Microbial Sensitivity Tests Mycobacterium tuberculosis - genetics |
| Title | Clinical utility of target-based next-generation sequencing for drug-resistant TB |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36853141 https://www.proquest.com/docview/2780764530 |
| Volume | 27 |
| WOSCitedRecordID | wos000992517700009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC6NdndZJOTqFi8tFSo0FvZZ1FKUtvU3-9sstWTIHjJbSFMJjvfNzN8H0I33NAooTYlOSQE4TqVRDpniTYyB3xqpElNbTYh-v1sNMoHoeG2CGuVqzuxvqhNqX2P_JaKDCg3T1h0N_sg3jXKT1eDhcY6ajGAMn6lS4y-pwjAbWrHXShiXpaRRo3GZpIA6Xt7r6amQ2nHT-p-R5d1lenu_vf99tBOwJf4vkmIfbRmiwO01QsT9EP0EoRApxgyzkNwXDrcrIMTX9EMLjwXntRq1P6j4bBsDSUOA8DFZr6cEODoHncWFR4-HKHX7tPw8ZkEWwWiuUgr4myuXKQEo5EQueSJUU6oVGlGlRfXYczpLHZxpjRUUGoTw5h1lGonpEgjQ4_RRlEW9hRhOMi5MVkG_Jwr5kVuHRdMRgaAZs7SNrpeBWsMaetnEbKw5XIx_glXG500ER_PGn2NsdfEZzGPz_5w-hxtewP4pilygVoOflp7iTb1Z_W2mF_V-QDP_qD3BazrwaM |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+utility+of+target-based+next-generation+sequencing+for+drug-resistant+TB&rft.jtitle=The+international+journal+of+tuberculosis+and+lung+disease&rft.au=Mansoor%2C+H&rft.au=Hirani%2C+N&rft.au=Chavan%2C+V&rft.au=Das%2C+M&rft.date=2023-01-01&rft.issn=1815-7920&rft.eissn=1815-7920&rft.volume=27&rft.issue=1&rft.spage=41&rft_id=info:doi/10.5588%2Fijtld.22.0138&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1815-7920&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1815-7920&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1815-7920&client=summon |